News & Media

Take a look inside our world

Press Releases

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total...

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maxi

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Sett...

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperi...

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone)

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovat...

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation a

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Confer...

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the T...

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatm

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool ...

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tende

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds...

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to R

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com


Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

“Real Progress Comes Not from Extraordinary Moments but from the Everyday”

“Real Progress Comes Not from Extraordinary Moments but from the Everyday”

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more